

CSD/BSE&NSE/NR/2021-22
August 16th, 2021

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: News Release

.....

With reference to above subject, please find enclosed News Release of our company Titled **“Suven Life sciences announces Phase 3 Clinical Trial of SUVN-502 (Masupirdine), a 5-HT6 antagonist for treatment of Agitation and aggression in Alzheimer’s type dementias”**

In this connection, in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended and in terms of the Code of Conduct of the Company for prevention of Insider Trading, the **"Trading Window"** for dealing in the securities of the Company shall remain closed for the Directors, Promoters, other Designated Persons, and immediate relatives of Designated Persons covered under the said code read with the SEBI Regulations, from 17th August 2021 to 18th August 2021 (both days inclusive). Please further note that Trading window will be opened from 19th August, 2021.

You are requested to take this notice on your record.

Thanking you,

Yours faithfully,
For **Suven Life Sciences Limited**



Shrenik Soni
Company Secretary

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com

News Release

Suven Life sciences announces Phase 3 Clinical Trial of SUVN-502 (Masupirdine), a 5-HT₆ antagonist for treatment of Agitation and aggression in Alzheimer's type dementias

HYDERABAD, INDIA (Aug 16, 2021) – Suven Life Sciences today informing that our NCE SUVN-502 (Masupirdine), a potent, selective, brain penetrant and orally active, novel chemical entity has planned initiation of global Phase 3 clinical trial for the treatment of Agitation and aggression in Alzheimer's type dementias with expected enrollment of patients from middle of September 2021. This multi-center study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result expected by the end of year 2024.

“Progression of SUVN-502 (Masupirdine) into Phase 3 clinical development is a significant achievement and milestone in enhancing our clinical pipeline. Our lead molecules address niche areas of cognitive impairment associated with neurodegenerative disorders”, said Venkat Jasti, CEO of Suven Life Sciences.

SUVN-502 (Masupirdine), a lead clinical candidate having undergone phase 2 study on 564 patients for moderate Alzheimer's disease without meeting primary end point. After an in-depth analysis of the data and intense dialogue with key opinion leaders, we have planned a new Clinical Trial for the treatment of Agitation and aggression in Alzheimer's type dementias.

Prior to the initiation of Phase 2A study, SUVN-502 has successfully undergone two phase 1 studies in Switzerland and USA on 122 healthy young and elderly male populations with no major adverse events and no serious adverse events.

About Suven Life Sciences

Suven Life Science is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, this Phase 3 SUVN-502 for Agitation and aggression in Alzheimer's type dementias, ongoing Phase 2 SUVN-G3031 for sleep disorders (Narcolepsy), Phase 1 completed SUVN-911 for Major Depression and Disorder (MDD) and Phase 1 completed SUVN-D4010, a Dual Mechanism of Action (Disease Modifying and Symptomatic Treatment Potential for AD) Gastro-Intestinal Motility Disorders. Apart from this Suven has 11 molecules in development pipeline.

For more information, please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com